Intracavernosal administration of papaverine or prostaglandin El for erectile impotence in paraplegics is being practised widely. One of the complications of this therapeutic regimen is prolonged erection which is at present being treated by aspiration of corporeal blood and intracavernosal administration of alpha adrenergic agonist such as phenylephrine. We report successful management of pharmacologically-induced prolonged erection in three traumatic paraplegics with oral terbutaline therapy. The indications for oral terbutaline therapy were (1) absence of significant coronary artery disease and (2) full erection persisting for more than 2� h, but less than 4 h duration. The initial dose of terbutaline was 5 mg and the same dose was repeated after 15 min as full erection persisted. Within the next 15 min, penile detumescence was achieved in two paraplegics with papaverine-induced prolonged erection. However, full erection still per sisted 15 min after the second dose of terbutaline in the third patient who had received intracavernosal administration of 3.25 p,g of prostaglandin El. There fore, he was given the third and final dose of 5 mg of terbutaline under cardiac monitoring. Penile detumescence was achieved within the next 15 min. It was ensured before administration of the third dose of terbutaline that (1) his blood pressure was within the normal range (for his paralysed status), (2) the heart rate was less than 100 per min and (3) there was no cardiac arrhythmia.
Introduction
Intracavernous self injection pharmaco therapy with papaverine for impotence has dramatically altered the therapeutic regi mens for erectile dysfunction during the past decade. However, the most significant com plication of pharmacologically stimulated erection is a prolonged erection which is dose related and is most frequently ob served in men with neuropathic or psycho genic impotence. The incidence of these prolonged erections reported in the literature ranges from 2% to 18%. 1 The standard therapy for pharmacologically induced prolonged erections is a combination of aspiration of up to 70 cc of corporeal blood and intracorporeal injection of alpha adrenergic agonist and smooth muscle contracting agents, such as phenylephrine, epinephrine, metaraminol and dopamine.
Intracavernous use of an alpha-adrenergic agonist should be taken seriously since two patients have died of acute severe hyper tension resulting from intracorporeal injection of metaraminol for priapism. 2 Alternatively, surgical procedures such as Winter's corporoglandular shunt may be carried out to achieve penile detumescence.
Oral medical therapy for the treatment of pharmacologically induced prolonged erec tions is more attractive than aspiration of corporeal blood, intracavernosal admini stration of an alpha-adrenergic agonist or a surgically created shunt procedure. Oral medical therapy can be instituted at an earlier time since the medication may be self administered by the patient at home at the appropriate time. It obviates the need for an emergency visit to a hospital for intra corporeal phenylephrine injection and its associated psychological sequelae.
It would be really embarrassing for a man to rush to the emergency department of a hospital in the middle of the night with pharmacologically induced prolonged erec tion. It has a demoralising effect upon the patient and his spouse as well. Self administered oral medical therapy for achieving penile detumescence can be prac tised by the patient himself in his home environment without rushing to a hospital. It is a boon to paraplegics and tetraplegics when they go on a holiday to a remote seaside resort where facilities for emergency transport and medical care are not readily available.
We describe our experience with oral administration of terbutaline for treatment of pharmacologically induced prolonged erection in paraplegics. This case illustrates the inefficacy of oral terbutaline therapy in cases of pharmacologic ally stimulated penile erection of more than 6 h duration. Preferably, terbutaline should not be administered in such cases as these patients will be treated subsequently with intracavernous phenylephrine to achieve penile detumescence. Controversy exists on (1) the optimum initial dose of terbutaline, (2) the time point at which the first dose of terbutaline should preferably be given and (3) how frequently it should be repeated. In cases of pharmaco logically induced prolonged erection, the sooner the oral terbutaline is given, the greater are the chances of it achieving penile detumescence. As illustrated by case 4, when penile erection had persisted for more than 6 h, oral terbutaline therapy was in effective. In prolonged erections of more than 6 h duration, ischaemia becomes ap parent with change of penile blood pH, p0 2 and pC0 2 and oral medication will have little chance of inducing detumescence. Drainage of blood and intracavernous injec tion of diluted alpha-adrenergic agent should be instituted to reverse the condition and prevent tissue damage. 6 Oral medical therapy with terbutaline is not recom mended in cases of prolonged erection of more than 6 h duration.
Case reports
In our clinical practice involving the care of spinal cord injured patients, we did not observe spontaneous occurrence of penile detumescence in any of our patients in whom full penile erection persisted at 4 h after intracavernosal administration of papaverine. Hence, we are anxious to in stitute oral medical therapy as early as possible in order to avoid the deleterious sequelae of persistent penile erection.
Understandably, we may be overtreating a few patients, but we believe that the bene fits of oral drug therapy in selected cases of pharmacologically induced persistent penile erection outweigh the risks involved, pro vided the medical therapy is carried out strictly in accordance with the protocol detailed below.
We prefer to start treatment with oral terbutaline for patients in whom full penile erection persisted for more than 2� h after intracavernosal administration of papaver ine or prostaglandin El. Provided he does not have significant coronary artery disease, we advocate self administration of an initial dose of 5 mg of terbutaline by mouth. The patient and/or his spouse should review the status of penile tumescence 15 min after oral administration of terbutaline. If penile erec tion is subsiding, further doses of terbut aline are not required. But a patient in whom full erection persists at 15 min after the inital dose of terbutaline is advised to take a second dose of 5 mg of terbutaline by mouth and to review the status of penile tumescence again after an interval of 15 min. If full erection persisted at 15 min after the second dose to terbutaline, he should go to the spinal injuries unit as quickly as possible.
When he arrives at the spinal Injuries unit, a doctor immediately carries out a careful assessment of his clinical status. The patient is attached to a cardiac monitor. If (1) his blood pressure is within the normal range (for his paralysed status), (2) the heart rate is less than 100 per min and (3) there is no evidence of cardiac arrhythmias, (4) full penile erection is still present, (5) the total duration of pharmacologically induced penile erection is not more than 4 h duration and (6) there is no hypokalaemia, he is given the third and final dose of 5 mg of terbutaline by mouth. As illustrated by case 3, this additional dose of terbutaline may help to achieve penile detumescence in selected patients who satisfy all the above mentioned criteria. After administration of the third dose of terbutaline, a physician stays with the patient for at least 1 h carefully observing his cardiac status. Some times after oral administration of terbut aline, ventricular premature contractions may be seen as happened in case 3. But as long as their frequency is less than 1 per min and as long as there is no (1) sequential ventricular depolarisations without inter vening sinus and beats, (2) multiform origin of premature ventricular contractions and (3) R on T phenomenon (premature ven tricular depolarisation occurs in the T wave of the preceding beat), careful observation Terbutaline for prolonged penile erection 673 of the patient may suffice; otherwise, sup pressive agents should be used. Serum potassium is again checked as overdose of beta-2 agonists may be associated with hypokalaemia which is probably caused by a redistribution of potassium from the plasma and extracellular fluid into the cells medi ated by an increase in intracellular 3-5 c AMP concentration. However, in the healthy heart, marked cardiac stimulation and hypokalaemia produced by beta-2 ago nists do not necessarily lead to the develop ment of cardiac arrhythmias.
In the unlikely event of full penile erec tion persisting at 30 min after the third dose of terbutaline, aspiration of corporeal blood and intracavernosal administration of phenylephrine (100 flg of phenylephrine diluted in 1 ml normal saline is administered slowly every 5 min up to a maximum dose of 500 flg or until penile detumescence is achieved, whichever is earlier) are carried out under cardiac monitoring to pharmaco logically contract the corporeal smooth muscle. The physician must be familiar with their use and must have vasodilators ready. Phenylephrine must not be given to hyper tensive patients and to those with arterio sclerotic coronary artery disease. In patients with significant coronary artery disease who have developed persistent penile erection after intracavernosal administration of papaverine or prostaglandin E1, neither terbutaline nor phenylephrine should be administered. The safest way of managing pharmacologically induced persistent penile erection in such patients is prompt aspira tion of corporeal blood which may have to be repeated. If arterial inflow is not reestab lished, as evidenced by persistent or recur rent dark corporeal aspirates, surgical shunting to the glans or corpus spongiosum should then be performed. Corporoglandu lar shunt (Winter'S procedure) may be performed with a Trucut needle (Baxter Health Care Ltd, Compton Newbury, UK) under local anaesthesia with lidocaine. Simi larly, terbutaline sulfate should not be used for treatment of pharmacologically induced prolonged penile erection in paraplegics who have other concomitant disease(s), such as (1) diabetes mellitus, (2) hyper tension, (3) hyperthyroidism, (4) a history of seizures, or in those spinal cord injured patients who are known to be hypersensitive to sympathomimetic agents.
In conclusion, we recommend initial treatment of selected cases of pharmaco logically induced prolonged penile erection with oral terbutaline sulfate; oral terbut aline therapy may obviate the need for an emergency visit to the hospital for intra coporeal phenylephrine injection.
